Table 3

 Genotype and haplotype distributions for the DLG5 and SLC22A4/SLC22A5 polymorphisms, respectively, and for the IGR2078a_1 marker

SNP markerGenotypeCrohn’s diseasep ValueUlcerative colitisp ValueControls
*615 patients with Crohn’s disease (CD), 355 patients with ulcerative colitis (UC), and 972 controls were tested for polymorphisms in the DLG5 gene.
†602 patients with CD, 357 patients with UC, and 1005 controls were tested for the IGR2078a_1 marker.
‡p values are given for the SLC22A4 1672TT, SLC22A5 −207CC, and IGR2078a_1AA genotypes; significance levels for the allele frequencies were p = 0.0041 for the 1672C→T polymorphism in SLC22A4, p = 0.0128 for the −207G→C polymorphism in SLC22A5, and p = 0.0128 for the IGR2078a_1 A/G marker; no significant differences for the heterozygous and carrier status (combined frequencies for homozygous and heterozygous genotypes with respect to the risk associated allele) were noted; these values were also significant after performing Bonferroni’s correction.
DLG5*
    113G→AGG501 (81.5%)NS284 (80.0%)NS781 (80.3%)
AG107 (17.4%)67 (18.9%)172 (17.7%)
AA7 (1.1%)4 (1.1%)19 (2.0%)
    4136C→ACC569 (92.5%)NS318 (89.6%)NS888 (91.4%)
AC44 (7.2%)34 (9.6%)82 (8.4%)
AA2 (0.3%)3 (0.8%)2 (0.2%)
    DLG5_e26insAinsA260 (42.3%)NS151 (42.5%)NS415 (42.7%)
insAdelA285 (46.3%)165 (46.5%)430 (44.2%)
delAdelA70 (11.4%)39 (11.0%)127 (13.1%)
SLC22A4
    1672C→TCC189 (30.2%)121 (33.3%)NS328 (32.4%)
CT283 (45.3%)180 (49.6%)518 (51.2%)
TT153 (24.5%)0.0005‡62 (17.1%)166 (16.4%)
SLC22A5
    −207G→CGG163 (26.1%)105 (28.9%)NS271 (26.8%)
GC282 (45.1%)170 (46.8%)533 (52.7%)
CC180 (28.8%)0.0009‡88 (24.3%)208 (20.5%)
OCTN haplotype
    SLC22A4/ C/G606 (48.5%)378 (52.1%)NS1075 (53.1%)
    SLC22A5 T/C587 (47.0%)0.0082302 (41.6%)850 (42.0%)
C/C55 (4.4%)44 (6.1%)99 (4.9%)
T/G2 (0.1%)2 (0.2%)0 (0.0%)
IGR2078a_1†
GG189 (31.4%)124 (34.7%)340 (33.8%)
GA279 (46.3%)179 (50.2%)507 (50.5%)
AA134 (22.3%)0.0013‡54 (15.1%)NS158 (15.7%)